GlassScriptPhysician profile
Alejandro Blanco-Franco
NPI 1699905208
$63,528.85
in general payments reported to CMS, 2019-2025
48 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $962 · 2021: $850 · 2022: $728 · 2023: $1,242 · 2024: $58K · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $57K · Food and Beverage: $3,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $56,700.00 |
| Food and Beverage | $3,273.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $56,724.23 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,290.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $826.12 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $575.41 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $465.29 | 2019-2024 | Xarelto |
| Pfizer INC. | $349.10 | 2019-2025 | |
| Glaxosmithkline, LLC. | $347.84 | 2019-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $291.89 | 2019-2022 | |
| Lilly USA, LLC | $277.73 | 2019-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.15 | 2019-2025 | Jardiance, Synjardy |
| Kerecis Limited | $258.72 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Novo Nordisk INC | $145.52 | 2020-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $140.08 | 2019-2021 | |
| Exact Sciences Corporation | $116.58 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $113.88 | 2022-2025 | Zoryve |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Blanco-Franco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.